MA45004A - Anticorps spécifiques anti-wt1-hla - Google Patents
Anticorps spécifiques anti-wt1-hlaInfo
- Publication number
- MA45004A MA45004A MA045004A MA45004A MA45004A MA 45004 A MA45004 A MA 45004A MA 045004 A MA045004 A MA 045004A MA 45004 A MA45004 A MA 45004A MA 45004 A MA45004 A MA 45004A
- Authority
- MA
- Morocco
- Prior art keywords
- specific antibodies
- hla specific
- hla
- antibodies
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239438P | 2015-10-09 | 2015-10-09 | |
| GBGB1517913.8A GB201517913D0 (en) | 2015-10-09 | 2015-10-09 | Anti-WT1/HLA-specific antibodies |
| EP15189753 | 2015-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45004A true MA45004A (fr) | 2019-03-27 |
Family
ID=58487775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045004A MA45004A (fr) | 2015-10-09 | 2016-10-04 | Anticorps spécifiques anti-wt1-hla |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10836829B2 (fr) |
| EP (1) | EP3359565A1 (fr) |
| JP (1) | JP6862435B2 (fr) |
| HK (1) | HK1258444A1 (fr) |
| MA (1) | MA45004A (fr) |
| WO (1) | WO2017060201A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4317432A3 (fr) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | Récepteurs de lymphocytes t à appariement amélioré |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3366704A1 (fr) * | 2017-02-28 | 2018-08-29 | Affimed GmbH | Anticorps spécifiques pour le complexe mmp1/hla-a2 |
| CA3065402A1 (fr) * | 2017-05-31 | 2018-12-06 | Carsgen Therapeutics Co., Ltd. | Compositions et methodes d'immunotherapie cellulaire |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス,アイエヌシー. | T細胞を製造する方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2020191172A1 (fr) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cultures de cellules t cd28, leurs compositions et leurs méthodes d'utilisation |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス,アイエヌシー. | 条件付きリガンド交換により産生されたペプチドmhc複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (fr) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Déplétion monocytaire des populations de lymphocytes t pour une thérapie par lymphocytes t |
| EP4408468A4 (fr) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | Formats multiples de complexes moléculaires |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| EP4514821A1 (fr) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Polypeptides d'il-12, polypeptides d'il-15, polypeptides d'il-18, polypeptides de cd8, compositions et leurs procédés d'utilisation |
| EP4514834A1 (fr) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Polypeptides récepteurs de tgfbêta négatifs dominants, polypeptides cd8, cellules, compositions et leurs méthodes d'utilisation |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| EP4661902A1 (fr) * | 2023-02-06 | 2025-12-17 | Memorial Sloan-Kettering Cancer Center | Compositions comprenant des anticorps anti-wt-1 et des fragments de liaison à l'antigène et utilisations associées |
| WO2025096649A1 (fr) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
| WO2026006495A1 (fr) * | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anticorps anti-wt1/hla-a2 et ses utilisations |
| WO2026096743A1 (fr) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Méthodes de fabrication de cellules t gamma delta |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012236068A1 (en) * | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US20140271644A1 (en) * | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
| ES2742224T3 (es) * | 2013-11-07 | 2020-02-13 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos anti-WT1/HLA |
| EP3066131A1 (fr) * | 2013-11-07 | 2016-09-14 | Memorial Sloan-Kettering Cancer Center | Anticorps anti-wt1/hla renforcé par fc |
| WO2015130766A1 (fr) * | 2014-02-25 | 2015-09-03 | Memorial Sloan-Kettering Cancer Center | Protéines se liant a l'antigène spécifiques du peptide de la tumeur de wilms 1 restreint à hla-a2 |
| WO2016174652A1 (fr) * | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Récepteurs antigéniques chimériques et méthodes d'utilisation correspondantes |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
-
2016
- 2016-10-04 JP JP2018518451A patent/JP6862435B2/ja not_active Expired - Fee Related
- 2016-10-04 EP EP16782018.2A patent/EP3359565A1/fr not_active Ceased
- 2016-10-04 HK HK19100718.0A patent/HK1258444A1/zh unknown
- 2016-10-04 WO PCT/EP2016/073587 patent/WO2017060201A1/fr not_active Ceased
- 2016-10-04 MA MA045004A patent/MA45004A/fr unknown
- 2016-10-07 US US15/288,145 patent/US10836829B2/en not_active Expired - Fee Related
-
2020
- 2020-10-13 US US17/069,136 patent/US20210024635A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6862435B2 (ja) | 2021-04-21 |
| HK1258444A1 (zh) | 2019-11-15 |
| JP2018536393A (ja) | 2018-12-13 |
| EP3359565A1 (fr) | 2018-08-15 |
| WO2017060201A1 (fr) | 2017-04-13 |
| US20210024635A1 (en) | 2021-01-28 |
| US10836829B2 (en) | 2020-11-17 |
| US20170101473A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3498840A4 (fr) | Anticorps anti-lag-3 | |
| EP3334757A4 (fr) | Anticorps anti-tigit | |
| EP3297671A4 (fr) | Anticorps anti-ror1 | |
| EP3423089A4 (fr) | Anticorps anti-tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| EP3589313A4 (fr) | Anticorps anti-tigit | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| EP3387442A4 (fr) | Anticorps anti-cd73 humanisés | |
| MA47472A (fr) | Anticorps | |
| EP3334824A4 (fr) | Anticorps anti-pd-1 | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| EP3319984C0 (fr) | Anticorps de liaison tau | |
| MA50352A (fr) | Anticorps multispécifiques | |
| MA53297A (fr) | Anticorps anti-icos | |
| EP3349787A4 (fr) | Anticorps cd47 thérapeutiques | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| IL256099A (en) | Antibody | |
| EP3319983C0 (fr) | Anticorps de liaison tau | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3492591A4 (fr) | Anticorps anti-b7-h4 | |
| EP3526247A4 (fr) | Anticorps anti-il1-rap | |
| DK3360890T3 (da) | Genterapi | |
| EP3399992A4 (fr) | Anticorps autoréticulants | |
| EP3484919A4 (fr) | Anticorps anti-bêta-amyloïde |